We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Near-Infrared Set-Up Evaluated for Dried Blood Spot Hematocrit

By LabMedica International staff writers
Posted on 11 Nov 2021
Capillary dried blood sampling, where samples are obtained from a finger or heel prick, has many advantages over traditional blood sampling. More...
The best-known dried blood sampling technique is the generation of dried blood spots (DBS) on filter paper.

Conventional DBS cards remain valuable to collect dried blood microsamples, not in the least because DBS sampling is well known in the newborn and pediatrics field, the analysis can easily be automated and the cost is low. Amongst the approaches that were developed to cope with this issue, is the hematocrit (Hct) prediction of DBS using near-infrared (NIR) spectroscopy.

Clinical Scientists at the Ghent University Hospital (Ghent, Belgium) and their colleagues collected blood from 12 healthy volunteers via finger prick and each volunteer provided three capillary DBS and three corresponding liquid capillary samples, the latter being collected via heparinized microcapillaries. Left-over venous EDTA-anti-coagulated patient samples were used to generate DBS by pipetting 25 µL of whole blood onto Whatman 903 filter paper.

The team determined Hct L/L (liter of cells/liter of blood) values with a Sysmex XN-5000 hematology analyzer (Sysmex, Kobe, Japan). The Hct of liquid capillary blood samples was determined via centrifugation in a Hct-centrifuge (5 minutes, 12,000 rpm), and then measured using a micro-hematocrit reader (Hawksley, Lancing, UK). NIR measurements were performed on a NIRFlex N-500 Fourier Transformation spectrometer equipped with a fiber optics solids cell N500-007 (Büchi Labortechnik, Flawil, Switzerland). The results obtained via NIR for the DBS validation set (n = 49; singlicate analysis), measured at Day 0 and Day 5, were compared to those obtained with the hematology analyzer, being the standard method.

Using left-over EDTA-anticoagulated patient samples, the accuracy and precision, stability, and robustness were assessed. Furthermore, applicability of the method on capillary DBS was evaluated via finger prick samples. The investigators reported that the method validation amply met the pre-set acceptance criteria, with a maximum total precision of 4.5% and bias of 0.012 L/L. Also storage did not relevantly affect the Hct prediction, except for storage at 60 °C. The analysis of samples with a high hemolytic/icteric/lipemic index (HIL)-index showed that only lipemia had a significant effect on the Hct predictions. The mean difference was 0.035 L/L, which was considered acceptable.

The authors concluded that a commercially available NIR set-up was extensively and successfully validated, allowing non-contact Hct prediction of DBS with excellent accuracy and precision. This allows to correct for the Hct-based bias observed in partial-punch DBS analysis and the set-up of blood-plasma conversion factors, increasing the application potential of patient-centric sampling. The study was published on October 5, 2021 in the journal Clinica Chimica Acta.

Related Links:
Ghent University Hospital
Sysmex
Hawksley
Büchi Labortechnik



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Urine Analyzer
respons® UDS100
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.